Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease

Keyphrases

• Confidence Interval 100%
• Crohn's Disease 100%
• Fish Oil 100%
• Omega-3 Fatty Acids 100%
• Maintenance of Remission 100%
• Risk Ratio 83%
• Risk of Bias 83%
• Pooled Analysis 50%
• High Risk 33%
• Low Risk 33%
• Placebo 33%
• Diarrhea 33%
• 3-group 33%
• Upper Gastrointestinal Tract 33%
• GRADE Analysis 33%
• Inflammatory Bowel Disease 16%
• Data Reporting 16%
• PubMed 16%
• Significant Benefit 16%
• Search Methods 16%
• Selection Criteria 16%
• Hazard Ratio 16%
• Treatment Group 16%
• Age Groups 16%
• Anti-inflammatory Effect 16%
• Disease Activity Score 16%
• Remission 16%
• Chronic Inflammatory Diseases 16%
• Omega-3 16%
• Random Effects 16%
• Adverse Events 16%
• MEDLINE 16%
• Embase 16%
• Cochrane Review 16%
• Possible Sources 16%
• Time-to-event Outcomes 16%
• Serious Adverse Events 16%
• Sparse Data 16%
• Sensitivity Analysis 16%
• Relapse Rate 16%
• Journal Club 16%
• Heterogeneity Analysis 16%
• Degree Heterogeneity 16%
• Time to First Relapse 16%
• Randomized Placebo-controlled Trial 16%
• Fixed Effects Model 16%
• RevMan 16%
• Cochrane 16%
• Risk of Bias Tool 16%
• Unknown Risks 16%
• Grading System 16%
• Selective Reporting 16%
• Publication Bias 16%
• Dichotomous Outcomes 16%
• Allocation Concealment 16%

Medicine and Dentistry

• Crohn's Disease 100%
• Omega-3 Fatty Acid 100%
• Placebo 75%
• Pooled Analysis 75%
• Adverse Event 50%
• Diarrhea 50%
• Upper Digestive Tract 50%
• Hazard Ratio 25%
• Inflammatory Bowel Disease 25%
• Antiinflammatory Activity 25%
• Inflammatory Disorder 25%
• Recurrence Risk 25%
• Disease Activity Score 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Remission 100%
• Crohn's Disease 100%
• Omega-3 Fatty Acid 100%
• Fish Oil 100%
• Placebo 50%
• Adverse Event 33%
• Diarrhea 33%
• Disease 16%
• Inflammatory Bowel Disease 16%
• Antiinflammatory Activity 16%
• Recurrence Risk 16%
• Disease Activity Score 16%